Moderna Net Worth (Updated 2025).

Moderna, a biotechnology company based in Cambridge, Massachusetts, was founded in 2010 by a group of highly accomplished scientists and entrepreneurs. The company’s mission was clear from the start: to develop a new class of medicines based on messenger RNA, or mRNA, a type of molecule that carries genetic instructions from DNA to make proteins.

In 2016, Moderna made its first splash in the public eye when it announced a $250 million investment from the Defense Advanced Research Projects Agency (DARPA). This funding was earmarked for the development of an mRNA vaccine for the Zika virus, a significant health concern at the time. This marked the beginning of Moderna’s rise to fame, as it demonstrated the potential of its innovative technology to address global health challenges.

Moderna’s Current Net Worth

As of 2025, Moderna’s market capitalization stands at an impressive $100 billion, making it one of the most valuable biotechnology companies globally. This significant figure reflects the company’s innovative work in developing messenger RNA (mRNA) vaccines and therapies.

Career

Founded in 2010, Moderna has swiftly established itself as a leader in the biotechnology industry. The company’s focus on mRNA technology has led to groundbreaking advancements, most notably the development of the COVID-19 vaccine in collaboration with the National Institutes of Health. This has significantly impacted global health and positioned Moderna at the forefront of vaccine innovation.

Other Ventures

Moderna’s portfolio extends beyond vaccines. The company is also exploring mRNA therapies for various diseases, including cancer, rare diseases, and infectious diseases. Additionally, it has partnerships with leading pharmaceutical companies like AstraZeneca and Merck to develop mRNA vaccines and therapies for a range of conditions.

Assets

Moderna’s primary assets include its extensive intellectual property portfolio, consisting of patents and trademarks related to mRNA technology. The company also has a robust pipeline of mRNA vaccines and therapies in various stages of development. Furthermore, Moderna’s manufacturing facilities, located in the United States and Europe, are strategic assets that enable the company to produce and distribute its products globally.

Annual Income

In 2024, Moderna reported a revenue of $21.5 billion, a significant increase from the previous year. This substantial growth can be attributed to the successful launch and sales of the COVID-19 vaccine. However, it’s important to note that the company’s financial performance may fluctuate in the coming years as it continues to diversify its product portfolio and expand into new therapeutic areas.

Frequently Asked Questions about  Moderna

Frequently Asked Questions: Moderna Net Worth

1. What is Moderna’s net worth?

Moderna’s net worth is estimated to be around $75 billion.

2. How does Moderna make money?

Moderna makes money primarily through the sale of its COVID-19 vaccine, SpikeVax, and its pipeline of mRNA vaccines for various diseases.

3. When was Moderna founded?

Moderna was founded in 2010.

4. Who is the CEO of Moderna?

Stéphane Bancel is the current CEO of Moderna.

5. What is mRNA technology?

mRNA, or messenger RNA, is a type of RNA that carries genetic information from DNA to the ribosome, where it is translated into proteins. Moderna uses this technology to create vaccines and therapeutics.

6. When was Moderna’s IPO?

Moderna’s initial public offering (IPO) was in December 2018.

7. What is the stock ticker symbol for Moderna?

The stock ticker symbol for Moderna is MRNA.

8. How many employees does Moderna have?

As of 2021, Moderna had around 1,500 employees.

9. What is the headquarters location of Moderna?

Moderna’s headquarters is located in Cambridge, Massachusetts, USA.

10. What are some of the diseases that Moderna is developing vaccines for?

Moderna is developing vaccines for a variety of diseases, including influenza, HIV, and cancer, in addition to its COVID-19 vaccine.